CAPILLARY: Q2 revenue grew 51% YoY as adjusted EBITDA margin reached 17%

What happened

Capillary reported that Q2 revenue grew 51% year over year and adjusted EBITDA margin reached 17%. First-half annual recurring revenue, or ARR, grew 51% to INR 1,085 crore. Management expects to meet or slightly exceed its full-year guidance, citing aiRA growth and SessionM integration as key drivers.

Confirmed

Global impact / market context

The reported growth and profitability measure suggest the business expanded sales while keeping adjusted operating costs in check. If aiRA growth and SessionM integration support the full-year outlook, they could help sustain recurring revenue; weaker execution could instead make guidance harder to achieve.

Analyst inference

The article gives growth rates and management’s outlook, but no share-price move, forecast comparison, or industry benchmarks. Investors therefore cannot tell from this information alone whether results beat expectations; the main business signal is whether recurring revenue growth translates into sustained revenue and profitability.

Analyst inference

What to watch

1. Check subsequent results against full-year guidance: management expects to meet or slightly exceed it, and reported revenue and adjusted EBITDA will show whether that outlook is being delivered. Confirmed
2. Look for updates on aiRA growth and SessionM integration, which management identified as drivers; clearer progress would help explain whether they contribute to recurring revenue and sales. Analyst inference
3. Compare later ARR growth with the reported 51% first-half increase to INR 1,085 crore; slower growth could weaken the recurring-revenue support for future sales. Analyst inference

Evidence

• Original source link unavailable